Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHesong ZouWHWenyang HuangDZDehui Zou

Discussion

Loading...

Member takes

Overview

Phase 2 trial demonstrates improved progression-free survival in high-risk aggressive B-cell lymphoma cases, highlighting efficacy of Polatuzumab vedotin.

Key Points

  • Best overall response rate reached 100%, with 81.3% achieving complete response due to Pola-R-EDCH treatment.
  • Among 16 patients, the 1-year progression-free survival rate was 62.5%, and overall survival rate was 87.5%.
  • Treatment included six cycles of Pola-R-EDCH, incorporating rituximab, etoposide, and dexamethasone for efficacy evaluation.
  • The results indicate Polatuzumab vedotin maintains efficacy without unexpected toxicities, especially in patients with TP53 mutations.

Cite This Study

Zou et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4fdhttps://doi.org/10.1182/blood-2025-3683
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data2025
  2. 2Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability2025
  3. 3Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study2025
  4. 4A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China2025
  5. 5Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization2025